NeuroMetrix (NSDQ:NURO) shares lost more than 4% of their value yesterday after the medical device company reported a more than 25% sales slide during the 3rd quarter.
Pain Management
FDA OKs clinical trial for Neuros Medical’s pain implant
Neuros Medical Inc. said it received an investigational device exemption from the FDA to run a clinical trial of its Altrius implantable generator to treat chronic pain in amputees.
The Altius device, consisting of an electrode and a generator, uses Neuros Medical’s patented electrical nerve block technology to deliver high-frequency stimulation to the peripheral nervous system to block chronic pain.
Supreme Court seeks White House opinion in Medtronic pain pump case
St. Jude-backed Spinal Modulation enrolls 1st patient in pain management study
Insightec lands Chinese approval for ExAblate ultrasound tumor ablation
Israeli device maker InSightec landed a green light from the Chinese Food & Drug Administration for its ExAblate MRI-guided focused ultrasound therapy, with an indication to treat non-cancer-causing tumors in the uterus.
These tumors, called uterine fibroids, occur in more than 20% of women of childbearing age, according to the company. ExAblate is an incision-free treatment that uses ultrasound frequencies to ablate tumors.
FDA green-lights NeuroMetrix pain treatment device for bed-time use
NeuroMetrix’s (NSDQ:NURO) Sensus wearable pain management device can now be paired with pajamas thanks to the FDA’s clearance of the device for use during sleep.
Medtronic’s latest pain pump warnings get FDA’s Class I status
More warnings for Medtronic’s SynchroMed implantable drug pumps
Class I recall for Symbios pain management kits
The FDA gave Class I status to the massive recall of Symbios pain management products, meaing the federal watchdog agency believes the devices could cause serious injury or death.
Symbios last month warned that components of its pain management kits made before July 2012 could deliver dangerously high drug-release flow rates, meaning patients could be poisoned by rapid medication influx.
Pain management: St. Jude pays $40M for exclusive purchase option for Spinal Modulation
St. Jude Medical (NYSE:STJ) last week branded neurostimulation devices maker Spinal Modulation as its territory with a $40 million equity investment that gives St. Jude international distribution rights and an exclusive option to acquire the company down the road.
Boston Scientific acquires, launches fiXate suturing system
Medical device maker Boston Scientific (NYSE:BSX) acquired the fiXate tissue band from Anulex Technologies, launching the suturing system right away.